Using CF0218-ELISA to distinguish Chlamydophila felis-infected cats from vaccinated and uninfected domestic cats
Using CF0218-ELISA to distinguish Chlamydophila felis-infected cats from vaccinated and uninfected domestic cats
复制标题
DOI：
10.1016/j.vetmic.2010.05.026
复制
发表时间：
2010-12-15
影响因子：
3.3
通讯作者：
Fukushi, Hideto
中科院分区：
文献类型：
--
作者：
Ohya, Kenji;Okuda, Hideko;Fukushi, Hideto
衣原菌是急性和慢性结膜炎和肺炎的病原体。猫可以接种死的或减毒的c。然而，目前的血清诊断不能将这些猫与自然感染的猫区分开来。这造成了早期诊断和血清流行病学调查的困难。我们之前报道过猫C.felis CF0218可以作为实验感染和/或接种猫C.felis感染的特异性诊断抗原。在这项研究中，我们评估了以重组CF0218为抗原的酶联免疫吸附法（CF0218- elisa）检测抗- c。已知接种过C型流感疫苗的714只家猫血清中存在猫抗体。44只接种过疫苗的猫，CF0218-ELISA检测93%阴性；其中一半的人用感染大肠杆菌的细胞作为抗原进行免疫荧光测定（IFA），结果呈阳性。670只未接种疫苗的猫的CF0218-ELISA阳性率在统计学上与IFA一致（18%对21%）。结果表明，CF0218是一种有效的血清诊断抗原，可用于区分自然感染的猫与接种疫苗的猫和未感染的猫。(C) 2010 Elsevier B.V.版权所有
Chlamydophila fells is a causative agent of acute and chronic conjunctivitis and pneumoniain cats. Cats can be vaccinated with killed or attenuated C. fells. However, current serodiagnostics cannot distinguish these cats from naturally infected cats. This causes difficulty of early diagnosis and seroepidemiological survey for C felis. We previously reported that C. felis CF0218 can be used as a C.felis-infection-specific diagnostic antigen in experimentally infected and/or vaccinated cats. In this study, we evaluated an enzyme-linked immunosorbent assay using recombinant CF0218 as antigen (CF0218-ELISA) to detect anti-C. felis antibody in 714 sera of domestic cats whose histories of vaccination against C fells are known. The 44 vaccinated cats were 93% negative using CF0218-ELISA; half of these scored positive by immunofluorescence assay (IFA) using C.felis-infected cells as antigen. The 670 non-vaccinated cats had CF0218-ELISA positivity rates that were statistically in agreement with IFA (18% vs. 21%). These results show that CF0218, which was identified as a C. fells-infection-specific antigen, is a useful serodiagnostic antigen to distinguish naturally C. fells-infected cats from vaccinated and non-infected cats. (C) 2010 Elsevier B.V. All rights reserved.